Literature DB >> 31567143

Potential Association of Doxycycline With the Onset of Primary Sclerosing Cholangitis: A Case Series.

James Gage Buness1, Ahmad Hassan Ali2,3, James H Tabibian4, Cynthia W Buness5, Kenneth L Cox6, Keith D Lindor1,2.   

Abstract

BACKGROUND: Primary sclerosing cholangitis (PSC) is linked to inflammatory bowel diseases (IBD). Evidence suggests an association between the gut microbiome and PSC. However, the putative relationship between exposure to antibiotics and onset of PSC has never been reported. We observed 3 cases in which patients without antecedent liver or bowel issues developed symptoms leading to diagnosis of IBD and subsequently PSC after being exposed to doxycycline. We aimed to identify, through the PSC Partners national patient registry, additional cases of PSC in which there is a temporal relationship between exposure to doxycycline and onset of PSC or PSC-IBD. AREAS OF UNCERTAINTY: The etiopathogenesis of PSC remains an enigma. DATA SOURCES: We collected data from patients with PSC and PSC-IBD in which there seemed to be a temporal relationship between exposure to doxycycline and PSC. Time from doxycycline exposure to: (1) onset of PSC or PSC-IBD symptoms and (2) diagnosis of PSC were documented for each patient. Descriptive statistical analyses were performed.
RESULTS: We identified 6 additional patients with PSC or PSC-IBD in whom there was a temporal relationship between exposure to doxycycline and onset of PSC or PSC-IBD. The median age of these 9 patients was 20 years, 6 were female, and 7 had ulcerative colitis. The median time from doxycycline exposure to onset of first symptoms was 3 months, and median time from doxycycline exposure to diagnosis of PSC was 15 months. THERAPEUTIC HYPOTHESIS: We describe 9 cases of PSC and PSC-IBD in which there seem to be a temporal relationship between exposure to doxycycline and onset of PSC.
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 31567143     DOI: 10.1097/MJT.0000000000001065

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   3.098


  1 in total

1.  Successful response of primary sclerosing cholangitis and associated ulcerative colitis to oral vancomycin may depend on brand and personalized dose: report in an adolescent.

Authors:  Cynthia W Buness; Kevin M Johnson; Ahmad Hassan Ali; Leina Alrabadi; Keith D Lindor; Tamir Miloh; Kenneth L Cox
Journal:  Clin J Gastroenterol       Date:  2020-11-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.